| Drug Name: | Propoxyphene (469-62-5) |
|---|---|
| PubChem ID: | 10100 |
| SMILES: | CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C |
| InchiKey: | XLMALTXPSGQGBX-GCJKJVERSA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 339.479 |
| LogP | : | 4.2755 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 3 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 29.54 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Carbamazepine (298-46-4) | Dizziness | Synergistic | Uncertain. It is suggested that dextropropoxyphene inhibits the metabolism of carbamazepine by the liver, leading to its accumulation in the body. | Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man |
| Orphenadrine (83-98-7) | Tremors | Antagonistic | Not Understood | Drug interaction? Orphenadrine with propoxyphene |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category